The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Sarah L. Booth - One of the best experts on this subject based on the ideXlab platform.

  • vitamin k status cardiovascular disease and all cause mortality a participant level meta analysis of 3 us cohorts
    The American Journal of Clinical Nutrition, 2020
    Co-Authors: Kyla M Shea, Sarah L. Booth, Kathryn Barger, Gregory Matuszek, Mary Cushman, Emelia J Benjamin, Stephen B Kritchevsky, Daniel E Weiner
    Abstract:

    Background Vitamin K-dependent proteins in vascular tissue affect vascular stiffness and calcification, which is associated with cardiovascular disease (CVD) and all-cause mortality. Objective To determine the association of circulating vitamin K concentrations with CVD and all-cause mortality by conducting a participant-level meta-analysis. Methods We obtained individual participant-level data from the Health, Aging, and Body Composition Study, the Multi-Ethnic Study of Atherosclerosis, and the Framingham Offspring Study, known cohorts with available measures of fasting circulating Phylloquinone (vitamin K-1) and confirmed CVD events and mortality. Circulating Phylloquinone was measured in a central laboratory from fasting blood samples and categorized as ≤0.5 nmol/L, >0.5-1.0 nmol/L, and >1.0 nmol/L. Multivariable Cox proportional hazard regression with multiple imputations was used to evaluate the association of circulating Phylloquinone with incident CVD and all-cause mortality risk. Results Among 3891 participants (mean age 65 ± 11 y; 55% women; 35% nonwhite), there were 858 incident CVD events and 1209 deaths over a median of 13.0 y. The risk of CVD did not significantly differ according to circulating Phylloquinone [fully adjusted HR (95% CI) relative to >1.0 nmol/L: ≤0.5 nmol/L, 1.12 (0.94, 1.33); >0.5-1.0 nmol/L, 1.02 (0.86, 1.20)]. Participants with ≤0.5 nmol/L circulating Phylloquinone had an adjusted 19% higher risk of all-cause mortality compared with those with >1.0 nmol/L [fully adjusted HR (95% CI): 1.19 (1.03, 1.38)]. Mortality risk was similar in participants with >0.5-1.0 nmol/L compared with >1.0 nmol/L [fully adjusted HR (95% CI): 1.04 (0.92, 1.17)]. Conclusions Low circulating Phylloquinone concentrations were associated with an increased risk of all-cause mortality, but not of CVD. Additional studies are needed to clarify the mechanism underlying this association and evaluate the impact of increased Phylloquinone intake on cardiovascular and other health outcomes in individuals with low vitamin K status.

  • associations of lipid related snps with circulating Phylloquinone are proportional with triglycerides p15 008 19
    Current Developments in Nutrition, 2019
    Co-Authors: Jennifer M Kelly, Hassan S Dashti, Caren E Smith, Jose M Ordovas, Gregory Matuszek, Gordon S Huggins, Sarah L. Booth
    Abstract:

    Phylloquinone is transported on triglyceride-rich lipoproteins. Preliminary evidence from a genome-wide association meta-analysis suggests that genetic variants that influence triglycerides (TGs), such as rs964184 at the APOA1/C3/A4/A5 gene cluster, also influence circulating Phylloquinone. To further evaluate this overlap, we examined the linear relationship between a weighted TG genetic risk score (wTG-GRS) with circulating Phylloquinone. We constructed a wTG-GRS comprised of 20 SNPs that were previously associated with TGs in a genome-wide association meta-analysis for blood lipids (n > 188,000 individuals of European ancestry). The assigned weights corresponded to the effect-sizes (β) reported for each SNP's association with TGs. With meta-analytic summary statistic data from a separate genome-wide association meta-analysis of circulating Phylloquinone (n = 2138 individuals of European ancestry), a statistical technique was used to approximate the linear association of the wTG-GRS with circulating Phylloquinone. A p-value of 0.05 for the estimate was considered statistically significant. First, the estimate was calculated without adjustment for TGs using Model 1 summary statistics, then calculated with adjustment for TGs using Model 2 summary statistics. The estimate for the linear association of the wTG-GRS with circulating Phylloquinone was significant without and with adjustment for TGs (Model 1: β = 0.052, P = < 0.0001, Model 2: β = 0.027, P = 0.0001, respectively). The goodness-of-fit of the model was improved from Model 1 (p-het = 0.022) to Model 2 (p-het = 0.054). The associations of TG-related SNPs with circulating Phylloquinone were proportional to their associations with TGs. This provides further evidence of the shared genetic links between TGs and Phylloquinone and suggests genetic studies of vitamin K should consider TGs. Study supported by the USDA Agricultural Research Service under Cooperative Agreement No. 58-1950-7-707 and NHLBI T32HL069772.

  • circulating Phylloquinone concentrations and risk of type 2 diabetes a mendelian randomization study
    Diabetes, 2019
    Co-Authors: Sabine R Zwakenberg, Sarah L. Booth, Hassan S Dashti, Sharon Remmelzwaal, Joline W J Beulens, Stephen Burgess, Fumiaki Imamura, Edith J M Feskens, Yvonne T Van Der Schouw
    Abstract:

    This study aims to investigate the causal relation between circulating Phylloquinone (vitamin K1) concentrations and type 2 diabetes using a Mendelian Randomization (MR) approach. We used data from thee cohorts: the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, Diabetes Genetics Replication and Meta-analysis (DIAGRAM) and the UK Biobank, resulting in 69,647 type 2 diabetes cases. We calculated a weighted genetic risk score including four genetic variants previously found to be associated with circulating Phylloquinone concentrations. Inverse-variance weighted analysis was used to obtain a risk ratio (RR) for the causal relation between circulating Phylloquinone concentrations and risk of type 2 diabetes. Presence of pleiotropy and the robustness of the results were assessed using MR-Egger and weighted-median analyses. Genetically-predicted concentrations of circulating Phylloquinone was associated with lower risk of type 2 diabetes with a RR of 0.93 (95% confidence interval: 0.89;0.97) per every ln-nmol/L unit increase in circulating Phylloquinone. The MR-Egger and weighted median analyses showed RRs of 0.94 (0.86;1.02) and 0.93 (0.88;0.98), respectively, indicating no pleiotropy. In conclusion, our study supports that higher circulating Phylloquinone may be causally related with lower risk of type 2 diabetes, highlighting the importance of sufficient Phylloquinone in the human diet.

  • reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary Phylloquinone and menaquinones
    European Journal of Clinical Nutrition, 2017
    Co-Authors: Sabine R Zwakenberg, Sarah L. Booth, Cees Vermeer, Edith J M Feskens, A I P Engelen, G W Dalmeijer, J J M M Drijvers, Marga C Ocke, Y T Van Der Schouw, Joline W J Beulens
    Abstract:

    Reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary Phylloquinone and menaquinones

  • vegetables and mixed dishes are top contributors to Phylloquinone intake in us adults data from the 2011 2012 nhanes
    Journal of Nutrition, 2017
    Co-Authors: Stephanie G Harshman, Emily G Finnan, Kathryn Barger, Regan L Bailey, David B Haytowitz, Cheryl H Gilhooly, Sarah L. Booth
    Abstract:

    Background: Phylloquinone is the most abundant form of vitamin K in US diets. Green vegetables are considered the predominant dietary source of Phylloquinone. As our food supply diversifies and expands, the food groups that contribute to Phylloquinone intake are also changing, which may change absolute intakes. Thus, it is important to identify the contributors to dietary vitamin K estimates to guide recommendations on intakes and food sources.Objective: The purpose of this study was to estimate 1) the amount of Phylloquinone consumed in the diet of US adults, 2) to estimate the contribution of different food groups to Phylloquinone intake in individuals with a high or low vegetable intake (≥2 or <2 cups vegetables/d), and 3) to characterize the contribution of different mixed dishes to Phylloquinone intake.Methods: Usual Phylloquinone intake was determined from NHANES 2011-2012 (≥20 y old; 2092 men and 2214 women) and the National Cancer Institute Method by utilizing a complex, stratified, multistage probability-cluster sampling design.Results: On average, 43.0% of men and 62.5% of women met the adequate intake (120 and 90 μg/d, respectively) for Phylloquinone, with the lowest self-reported intakes noted among men, especially in the older age groups (51-70 and ≥71 y). Vegetables were the highest contributor to Phylloquinone intake, contributing 60.0% in the high-vegetable-intake group and 36.1% in the low-vegetable-intake group. Mixed dishes were the second-highest contributor to Phylloquinone intake, contributing 16.0% in the high-vegetable-intake group and 28.0% in the low-vegetable-intake group.Conclusion: Self-reported Phylloquinone intakes from updated food composition data applied to NHANES 2011-2012 reveal that fewer men than women are meeting the current adequate intake. Application of current food composition data confirms that vegetables continue to be the primary dietary source of Phylloquinone in the US diet. However, mixed dishes and convenience foods have emerged as previously unrecognized but important contributors to Phylloquinone intake in the United States, which challenges the assumption that Phylloquinone intake is a marker of a healthy diet. These findings emphasize the need for the expansion of food composition databases that consider how mixed dishes are compiled and defined.

Martin J Shearer - One of the best experts on this subject based on the ideXlab platform.

  • the external quality assurance of Phylloquinone vitamin k1 analysis in human serum
    Biomedical Chromatography, 2009
    Co-Authors: David J Card, Martin J Shearer, Leon J Schurgers, Dominic J Harrington
    Abstract:

    The vitamin K external quality assurance scheme (KEQAS) aims to assist in the harmonization of Phylloquinone (vitamin K1) analysis in order to improve the comparability of clinical and nutritional studies. Serum samples were despatched to 17 groups from eight countries during 2000–2006. Using pilot data (1996–1999), an analytical performance target of 20% absolute difference from the all-laboratory trimmed mean (ALTM) was assigned and formed the basis for interlaboratory comparison. Assay specificity, analytical bias and assay performance were evaluated. From 21 batches of samples distributed, 414 results were reported of which 2.7% were outliers. The mean interlaboratory absolute difference from the ALTM was 21.7% with 47% of groups consistently meeting the performance target. The mean interlaboratory coefficient of variation was 29.6%. The false positive rate for Phylloquinone depleted samples was high at 35%. Bias was found to be independent of HPLC-detector type (fluorescence vs electrochemical). Assay characteristics for the measurement of Phylloquinone in human serum compare favourably with methods for analytes at equivalent concentrations. The high proportion of false positive results suggest that poor assay specificity at low Phylloquinone concentrations is a common problem, which in the clinical setting could lead to underreporting of vitamin K deficiency. Copyright © 2009 John Wiley & Sons, Ltd.

  • metabolism and cell biology of vitamin k
    Thrombosis and Haemostasis, 2008
    Co-Authors: Martin J Shearer, Paul Newman
    Abstract:

    Naturally occurring vitamin K compounds comprise a plant form, Phylloquinone (vitamin K(1)) and a series of bacterial menaquinones (MKs) (vitamin K(2)). Structural differences in the isoprenoid side chain govern many facets of metabolism of K vitamins including the way they are transported, taken up by target tissues, and subsequently excreted. In the post-prandial state, Phylloquinone is transported mainly by triglyceride-rich lipoproteins (TRL) and long-chain MKs mainly by low-density lipoproteins (LDL). TRL-borne Phylloquinone uptake by osteoblasts is an apoE-mediated process with the LRP1 receptor playing a predominant role. One K(2) form, MK-4, has a highly specific tissue distribution suggestive of local synthesis from Phylloquinone in which menadione is an intermediate. Both Phylloquinone and MKs activate the steroid and xenobiotic receptor (SXR) that initiates their catabolism, but MK-4 specifically upregulates two genes suggesting a novel MK-4 signalling pathway. Many studies have shown specific clinical benefits of MK-4 at pharmacological doses for osteoporosis and cancer although the mechanism(s) are poorly understood. Other putative non-cofactor functions of vitamin K include the suppression of inflammation, prevention of brain oxidative damage and a role in sphingolipid synthesis. Anticoagulant drugs block vitamin K recycling and thereby the availability of reduced vitamin K. Under extreme blockade, vitamin K can bypass the inhibition of Gla synthesis in the liver but not in the bone and the vessel wall. In humans, MK-7 has a greater efficacy than Phylloquinone in carboxylating both liver and bone Gla proteins. A daily supplement of Phylloquinone has shown potential for improving anticoagulation control.

  • excretion of the urinary 5c and 7c aglycone metabolites of vitamin k by young adults responds to changes in dietary Phylloquinone and dihydroPhylloquinone intakes
    Journal of Nutrition, 2007
    Co-Authors: Dominic J Harrington, Sarah L. Booth, David J Card, Martin J Shearer
    Abstract:

    The physiological function and putative health roles of vitamin K-dependent proteins now extend beyond their classical role in hemostasis and include bone mineralization, arterial calcification, apoptosis, phagocytosis, growth control, chemotaxis, and signal transduction. Current assessments of vitamin K status do not reflect the variety of molecular forms of vitamin K. We assessed whether urinary excretion of 2-methyl-3-(5'-carboxy-3'-methyl-2'-pentenyl)-1,4-naphthoquinone (7C-aglycone) and 2-methyl-3-(3'-3'-carboxymethylpropyl)-1,4-naphthoquinone (5C-aglycone), vitamin K metabolites common to both Phylloquinone and the menaquinone series, reflect dietary vitamin K intake. In a randomized crossover study, 9 adults resided in a metabolic unit for two 30-d periods separated by a free-living period of > or = 4 wk. During each residency, subjects consumed 3 sequential diets: a control diet (93 microg Phylloquinone/d) for 5 d, a Phylloquinone-restricted diet (11 microg/d) for 15 d, followed by a randomly assigned repletion diet for 10 d with either Phylloquinone (206 microg/d) or dihydroPhylloquinone (240 microg/d). During the second residency, the alternative repletion diet was assigned. Urinary excretion of the 5C- and 7C-aglycones was measured in sequential 24-h collections. The 5C-aglycone accounted for approximately 75% of total excretion and declined in response to Phylloquinone restriction (P = 0.001) to approximately 30% of that during the control diet period. Repletion with Phylloquinone and dihydroPhylloquinone doubled the excretion rate of the major 5C-aglycone by 24 h (P < 0.001), and tripled excretion by 4 d. There was a linear relationship between the logarithm of total urinary excretion and dietary vitamin K intake (r = 0.699, P < 0.001). We conclude that the urinary excretion of vitamin K metabolites reflects dietary Phylloquinone intake and offers the first candidate marker of global vitamin K status.

  • ethnic differences in osteocalcin γ carboxylation plasma Phylloquinone vitamin k1 and apolipoprotein e genotype
    European Journal of Clinical Nutrition, 2005
    Co-Authors: Dominic J Harrington, A M Prentice, S R Beavan, Dorothy M Stirling, Bakary Dibba, L Yan, Martin J Shearer
    Abstract:

    Objective: To investigate plasma osteocalcin γ-carboxylation and its relationship to plasma Phylloquinone concentration and apolipoprotein E (apoE) genotype in women from three ethnic groups with differing osteoporotic fracture risk. Design and subjects: Fasted blood samples were collected from postmenopausal Gambian (n=50), British (n=31) and Chinese women (n=23), and 11 premenopausal women in each group from three cross-sectional studies. Results: After adjustment for total osteocalcin, plasma undercarboxylated osteocalcin (adjusted ucOC) was lowest in Chinese and highest in British women postmenopause (British vs Chinese 103% higher, P<0.0001; Gambian vs Chinese 66% higher, P<0.01). No differences were observed premenopause. Within each ethnic group, adjusted ucOC was similar pre- and postmenopause. Postmenopause, plasma Phylloquinone was higher in Chinese women (1.0 ng/ml) than in British (0.31 ng/ml) and Gambian women (0.36 ng/ml) (P<0.0001). Premenopause, plasma Phylloquinone was higher in Gambian and Chinese women (0.6 ng/ml) than in British women (0.3 ng/ml; P=0.01). Plasma Phylloquinone and adjusted ucOC were inversely related in postmenopausal British women (R2=32.4%; P=0.0008). ApoE4 frequency was Gambian 32.6%, British 13.8% and Chinese 6%. A lower adjusted ucOC was associated with apoE2 genotype in British and Chinese women. Ethnic differences in adjusted ucOC persisted after adjustment for Phylloquinone and apoE genotype. Conclusion: These preliminary data indicate suboptimal vitamin K status in postmenopausal British compared to Chinese and Gambian women. Ethnic differences in apoE genotype may also influence osteocalcin γ-carboxylation status. The study highlights the need for larger epidemiological investigations of ethnic differences in vitamin K status and the possible implications to bone health. Sponsorship: This work was funded by the MRC.

  • plasma Phylloquinone vitamin k1 concentration and its relationship to intake in a national sample of british elderly people
    British Journal of Nutrition, 2002
    Co-Authors: C W Thane, C J Bates, Martin J Shearer, N Unadkat, Dominic J Harrington, A A Paul, A M Prentice, C Boltonsmith
    Abstract:

    Abstract Plasma Phylloquinone (vitamin K1) concentration was examined according to season, socio-demographic and lifestyle factors and Phylloquinone intake in a nationally representative sample of British people aged 65 years and over from the 1994-5 National Diet and Nutrition Survey. Values for both plasma Phylloquinone concentration and Phylloquinone intake were available from 1076 participants (561 men, 515 women). Eight hundred and thirty-four were living in private households, 242 in residential or nursing homes. Weighted geometric mean plasma Phylloquinone concentrations were 0.36 (inner 95% range [corrected] 0.06, 2.01) and 0.24 (inner 94% range [corrected] 0.06, 0.96) nmol/l in free-living and institution samples respectively. Plasma Phylloquinone concentrations did not generally differ between men and women, although values in free-living people were significantly lower during autumn and winter (October to March). Plasma Phylloquinone concentration was not significantly associated with age. Plasma Phylloquinone concentrations were positively correlated with Phylloquinone intake in free-living men and women (r 0.18 and 0.30 respectively, both P<0.001). Stepwise multiple regression analysis found that 11 % of the variation in plasma Phylloquinone concentration was explained by Phylloquinone intake, season and plasma triacylglycerol concentration. After adjustment for age and corresponding nutrient intakes, plasma Phylloquinone concentration was significantly associated (each P<0.01) with plasma concentrations of triacylglycerol, cholesterol, retinol and 25-hydroxyvitamin D in free-living women but not men, and with plasma concentrations of carotenes, alpha- and gamma-tocopherols and lutein in free-living men and women. The possibility of concurrent low fat-soluble vitamin status in elderly populations may be a cause for concern.

Joline W J Beulens - One of the best experts on this subject based on the ideXlab platform.

  • Circulating Phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: A two-sample Mendelian Randomization study.
    'Organisation for Economic Co-Operation and Development (OECD)', 2020
    Co-Authors: Zwakenberg, Sabine R, Joline W J Beulens, Burgess Stephen, Sluijs Ivonne, Weiderpass Elisabete, Epic-cvd Consortium, Van Der Schouw, Yvonne T
    Abstract:

    Background and aims: Multiple observational studies and small-scale intervention studies suggest that high vitamin K intake is associated with improved markers for cardiovascular health. Circulating Phylloquinone solely represents Phylloquinone (vitamin K1) intake, while dephosphorylated uncarboxylated Matrix Gla Protein (dp-ucMGP) represents both Phylloquinone and menaquinone (vitamin K2) intake. This study aims to investigate the causal relationship between genetically predicted vitamin K concentrations and the risk of CHD via a two-sample Mendelian Randomization approach. Design: We used data from three studies: the European Prospective Investigation into Cancer and Nutrition (EPIC)-CVD case-cohort study, CARDIOGRAMplusC4D and the UK Biobank, resulting in 103,097 CHD cases. Genetically predicted vitamin K concentrations were measured using SNPs related to circulating Phylloquinone and dp-ucMGP. We calculated a genetic risk score (GRS) including four SNPs (rs2108622, rs2192574, rs4645543 and rs6862071) related to circulating Phylloquinone levels from a genome wide association study. Rs4236 was used as an instrumental variable for dp-ucMGP. Inverse-variance weighted (IVW) analysis was used to obtain Risk Ratios (RRs) for the causal relationship between Phylloquinone and dp-ucMGP concentrations and CHD risk. Results: Using the genetic score for circulating Phylloquinone, we found that circulating Phylloquinone was not causally related to CHD risk (RR 1.00 (95%-CI: 0.98;1.04)). Lower genetically predicted dp-ucMGP concentration was associated with a lower CHD risk with a RR of 0.96 (95%-CI: 0.93;0.99) for every 10 μg/L decrease in dp-ucMGP. Conclusions: This study did not confirm a causal relationship between circulating Phylloquinone and lower CHD risk. However, lower dp-ucMGP levels may be causally related with a decreased CHD risk. This inconsistent result may reflect the influence of menaquinones in the association with CHD.Includes FP7, EU, MRC, NIHR and BH

  • circulating Phylloquinone concentrations and risk of type 2 diabetes a mendelian randomization study
    Diabetes, 2019
    Co-Authors: Sabine R Zwakenberg, Sarah L. Booth, Hassan S Dashti, Sharon Remmelzwaal, Joline W J Beulens, Stephen Burgess, Fumiaki Imamura, Edith J M Feskens, Yvonne T Van Der Schouw
    Abstract:

    This study aims to investigate the causal relation between circulating Phylloquinone (vitamin K1) concentrations and type 2 diabetes using a Mendelian Randomization (MR) approach. We used data from thee cohorts: the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, Diabetes Genetics Replication and Meta-analysis (DIAGRAM) and the UK Biobank, resulting in 69,647 type 2 diabetes cases. We calculated a weighted genetic risk score including four genetic variants previously found to be associated with circulating Phylloquinone concentrations. Inverse-variance weighted analysis was used to obtain a risk ratio (RR) for the causal relation between circulating Phylloquinone concentrations and risk of type 2 diabetes. Presence of pleiotropy and the robustness of the results were assessed using MR-Egger and weighted-median analyses. Genetically-predicted concentrations of circulating Phylloquinone was associated with lower risk of type 2 diabetes with a RR of 0.93 (95% confidence interval: 0.89;0.97) per every ln-nmol/L unit increase in circulating Phylloquinone. The MR-Egger and weighted median analyses showed RRs of 0.94 (0.86;1.02) and 0.93 (0.88;0.98), respectively, indicating no pleiotropy. In conclusion, our study supports that higher circulating Phylloquinone may be causally related with lower risk of type 2 diabetes, highlighting the importance of sufficient Phylloquinone in the human diet.

  • reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary Phylloquinone and menaquinones
    European Journal of Clinical Nutrition, 2017
    Co-Authors: Sabine R Zwakenberg, Sarah L. Booth, Cees Vermeer, Edith J M Feskens, A I P Engelen, G W Dalmeijer, J J M M Drijvers, Marga C Ocke, Y T Van Der Schouw, Joline W J Beulens
    Abstract:

    Reproducibility and relative validity of a food frequency questionnaire to estimate intake of dietary Phylloquinone and menaquinones

  • Phylloquinone concentrations and the risk of vascular calcification in healthy women
    Arteriosclerosis Thrombosis and Vascular Biology, 2014
    Co-Authors: Geertje W Dalmeijer, Sarah L. Booth, Yvonne T Van Der Schouw, Pim A De Jong, Joline W J Beulens
    Abstract:

    Objective—To investigate the association of plasma Phylloquinone concentrations with coronary artery calcification (CAC) and vascular calcification. Approach and results—In a prospective cohort of 508 postmenopausal women, plasma Phylloquinone concentrations were measured by high-pressure liquid chromatography. Calcification was measured in the coronary arteries, aortic valve, mitral valve, and thoracic aorta by multidetector computed tomography. To combine these calcification scores, we dichotomized each of the 4 areas into present or absent. Because of the continuous measurement of CAC, we categorized this as calcification present if Agatston score was >0, and calcification score was calculated as the sum of the calcified areas. Multivariate-adjusted prevalence ratios and odds ratios were estimated using Poisson regression and multinomial logistic regression. After 8.5 years of follow-up, 22% of the women had no calcification, whereas 5% had calcification in all measured areas. Detectable Phylloquinone ...

  • intake of dietary Phylloquinone and menaquinones and risk of stroke
    Journal of the American Heart Association, 2013
    Co-Authors: Linda E T Vissers, Yvonne T Van Der Schouw, Geertje W Dalmeijer, Jolanda M A Boer, W Monique M Verschuren, Joline W J Beulens
    Abstract:

    Background Dietary vitamin K intake is thought to decrease the risk of cardiovascular disease (CVD) by reducing vascular calcification, although vitamin K is also involved in coagulation. Studies investigating the association between Phylloquinone intake and risk of stroke are scarce, and the relation with menaquinones has not been investigated to date. Methods and Results We investigated the association between intake of Phylloquinone and menaquinones and stroke in a prospective cohort of 35 476 healthy subjects. Information on occurrence of stroke was obtained by linkage to national registries, and stroke was further specified into ischemic and hemorrhagic stroke. Vitamin K intake was estimated using a validated food-frequency questionnaire. Multivariate Cox proportional hazards models adjusted for cardiovascular risk factors, lifestyle, and other dietary factors were used to estimate the associations. During a follow-up of 12.1±2.1 years, 580 incident cases of stroke were identified, 163 of which were hemorrhagic and 324 were ischemic. Phylloquinone intake was not associated with risk of stroke with a hazard ratio (HR) of 1.09 (95% CI: 0.85 to 1.40, P trend 0.41) for the highest versus lowest quartile. For intake of menaquinones similar results were found, with an HRQ4 versus Q1 of 0.99 (95% CI: 0.75 to 1.29, P trend 0.82). When specifying hemorrhagic and ischemic stroke or menaquinone subtypes, no significant associations were detected. Conclusion In our study, neither dietary Phylloquinone nor dietary menaquinones intake were associated with stroke risk.

Yvonne T Van Der Schouw - One of the best experts on this subject based on the ideXlab platform.

  • circulating Phylloquinone concentrations and risk of type 2 diabetes a mendelian randomization study
    Diabetes, 2019
    Co-Authors: Sabine R Zwakenberg, Sarah L. Booth, Hassan S Dashti, Sharon Remmelzwaal, Joline W J Beulens, Stephen Burgess, Fumiaki Imamura, Edith J M Feskens, Yvonne T Van Der Schouw
    Abstract:

    This study aims to investigate the causal relation between circulating Phylloquinone (vitamin K1) concentrations and type 2 diabetes using a Mendelian Randomization (MR) approach. We used data from thee cohorts: the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, Diabetes Genetics Replication and Meta-analysis (DIAGRAM) and the UK Biobank, resulting in 69,647 type 2 diabetes cases. We calculated a weighted genetic risk score including four genetic variants previously found to be associated with circulating Phylloquinone concentrations. Inverse-variance weighted analysis was used to obtain a risk ratio (RR) for the causal relation between circulating Phylloquinone concentrations and risk of type 2 diabetes. Presence of pleiotropy and the robustness of the results were assessed using MR-Egger and weighted-median analyses. Genetically-predicted concentrations of circulating Phylloquinone was associated with lower risk of type 2 diabetes with a RR of 0.93 (95% confidence interval: 0.89;0.97) per every ln-nmol/L unit increase in circulating Phylloquinone. The MR-Egger and weighted median analyses showed RRs of 0.94 (0.86;1.02) and 0.93 (0.88;0.98), respectively, indicating no pleiotropy. In conclusion, our study supports that higher circulating Phylloquinone may be causally related with lower risk of type 2 diabetes, highlighting the importance of sufficient Phylloquinone in the human diet.

  • Phylloquinone concentrations and the risk of vascular calcification in healthy women
    Arteriosclerosis Thrombosis and Vascular Biology, 2014
    Co-Authors: Geertje W Dalmeijer, Sarah L. Booth, Yvonne T Van Der Schouw, Pim A De Jong, Joline W J Beulens
    Abstract:

    Objective—To investigate the association of plasma Phylloquinone concentrations with coronary artery calcification (CAC) and vascular calcification. Approach and results—In a prospective cohort of 508 postmenopausal women, plasma Phylloquinone concentrations were measured by high-pressure liquid chromatography. Calcification was measured in the coronary arteries, aortic valve, mitral valve, and thoracic aorta by multidetector computed tomography. To combine these calcification scores, we dichotomized each of the 4 areas into present or absent. Because of the continuous measurement of CAC, we categorized this as calcification present if Agatston score was >0, and calcification score was calculated as the sum of the calcified areas. Multivariate-adjusted prevalence ratios and odds ratios were estimated using Poisson regression and multinomial logistic regression. After 8.5 years of follow-up, 22% of the women had no calcification, whereas 5% had calcification in all measured areas. Detectable Phylloquinone ...

  • intake of dietary Phylloquinone and menaquinones and risk of stroke
    Journal of the American Heart Association, 2013
    Co-Authors: Linda E T Vissers, Yvonne T Van Der Schouw, Geertje W Dalmeijer, Jolanda M A Boer, W Monique M Verschuren, Joline W J Beulens
    Abstract:

    Background Dietary vitamin K intake is thought to decrease the risk of cardiovascular disease (CVD) by reducing vascular calcification, although vitamin K is also involved in coagulation. Studies investigating the association between Phylloquinone intake and risk of stroke are scarce, and the relation with menaquinones has not been investigated to date. Methods and Results We investigated the association between intake of Phylloquinone and menaquinones and stroke in a prospective cohort of 35 476 healthy subjects. Information on occurrence of stroke was obtained by linkage to national registries, and stroke was further specified into ischemic and hemorrhagic stroke. Vitamin K intake was estimated using a validated food-frequency questionnaire. Multivariate Cox proportional hazards models adjusted for cardiovascular risk factors, lifestyle, and other dietary factors were used to estimate the associations. During a follow-up of 12.1±2.1 years, 580 incident cases of stroke were identified, 163 of which were hemorrhagic and 324 were ischemic. Phylloquinone intake was not associated with risk of stroke with a hazard ratio (HR) of 1.09 (95% CI: 0.85 to 1.40, P trend 0.41) for the highest versus lowest quartile. For intake of menaquinones similar results were found, with an HRQ4 versus Q1 of 0.99 (95% CI: 0.75 to 1.29, P trend 0.82). When specifying hemorrhagic and ischemic stroke or menaquinone subtypes, no significant associations were detected. Conclusion In our study, neither dietary Phylloquinone nor dietary menaquinones intake were associated with stroke risk.

  • dietary Phylloquinone and menaquinones intakes and risk of type 2 diabetes
    Diabetes Care, 2010
    Co-Authors: Joline W J Beulens, Daphne L Van Der A, Diederick E Grobbee, Ivonne Sluijs, Annemieke M W Spijkerman, Yvonne T Van Der Schouw
    Abstract:

    OBJECTIVE To investigate whether dietary Phylloquinone and menaquinones intakes are related to risk of type 2 diabetes. RESEARCH DESIGN AND METHODS We used data from a prospective cohort study in 38,094 Dutch men and women, aged 20–70 years. Dietary Phylloquinone and menaquinones intakes were assessed using a validated food frequency questionnaire. Diabetes case patients were ascertained mainly via self-report and verified against medical records. RESULTS During 10.3 years of follow-up, 918 incident cases of diabetes were documented. In a multivariate model adjusting for diabetes risk factors and dietary factors, Phylloquinone intake tended to be associated ( P = 0.08) with a reduced risk of type 2 diabetes with a hazard ratio (HR) of 0.81 (95% CI 0.66–0.99) for the highest versus the lowest quartile. For menaquinones intake, a linear, inverse association ( P = 0.038) with risk of type 2 diabetes was observed with an HR of 0.93 (0.87–1.00) for each 10-μg increment in the multivariate model. CONCLUSIONS This study shows that both Phylloquinone and menaquinones intakes may be associated with a reduced risk of type 2 diabetes.

James A. Sadowski - One of the best experts on this subject based on the ideXlab platform.

  • plasma lipoproteins as carriers of Phylloquinone vitamin k1 in humans
    The American Journal of Clinical Nutrition, 1998
    Co-Authors: Stefania Lamonfava, K. W. Davidson, James A. Sadowski, M E Obrien, Judith R Mcnamara, Ernst J Schaefer
    Abstract:

    The purpose of this study was to characterize the absorption and transport of Phylloquinone (vitamin K1) by plasma lipoproteins. Twenty-six healthy subjects (11 men and 15 women) aged 20-78 y received Phylloquinone in the amount of either 1.43 or 50 microg/kg body wt orally with a fat-rich meal containing 1.0 g/kg body wt of fat, carbohydrate, and protein and 7.0 mg cholesterol/kg body wt. Blood was obtained at baseline (0 h) and 3, 6, 9, and 12 h after the meal for the measurement of plasma lipid and Phylloquinone concentrations in plasma and lipoprotein subfractions. In both groups of subjects, triacylglycerol concentrations peaked after 3 h in plasma and in the triacylglycerol-rich lipoprotein fraction, composed of chylomicrons and VLDLs. Plasma Phylloquinone concentrations peaked at 6 h. At baseline and during the postprandial phase, > 53% of plasma Phylloquinone was carried by the triacylglycerol-rich lipoprotein fraction. In 9 of the 11 subjects supplemented with 50 microg Phylloquinone/kg, plasma lipoproteins were isolated by sequential ultracentrifugation. In these subjects the fraction of plasma Phylloquinone carried by LDLs and by HDLs increased progressively from 3% and 4% at 3 h to 14% and 11% at 12 h, respectively. Our data indicate that whereas triacylglycerol-rich lipoproteins are the major carriers of Phylloquinone, LDL and HDL may carry small fractions of this vitamin.

  • Changes in serum osteocalcin, plasma Phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary Phylloquinone in human subjects.
    The American Journal of Clinical Nutrition, 1997
    Co-Authors: Lori J. Sokoll, M. E. O'brien, K. W. Davidson, Katherine I. Tsaioun, Sarah L. Booth, James A. Sadowski
    Abstract:

    : The response of osteocalcin and other biochemical markers of vitamin K status to diets formulated to contain different amounts of Phylloquinone was assessed in nine healthy subjects aged 20-33 y. Subjects resided in a metabolic ward for two 15-d cycles with a minimum of 6 wk between cycles. A mixed diet containing 100 micrograms Phylloquinone/d was fed throughout both cycles; however, the Phylloquinone content of one of the cycles was increased to a total of 420 micrograms/d on days 6 through 10 by fortifying corn oil in the diet with Phylloquinone (supplemented diet). Total serum osteocalcin concentrations were not affected by either of the dietary treatments. The percentage of undercarboxylated osteocalcin increased an average of 28% over the 15-d cycle with the mixed diet (P < 0.05) and declined significantly an average of 41% with 5 d of the supplemented diet (day 6: 21.9 +/- 1.3%, day 11: 12.8 +/- 1.1%; P = 0.0001) with a rise after the return to the mixed diet (16.7 +/- 1.3%, P < 0.001). Plasma Phylloquinone concentrations increased significantly with supplementation (day 6: 0.95 +/- 0.16 nmol/L, day 11: 1.40 +/- 0.29 nmol/L; P < 0.001) and then rapidly returned to presupplementation concentrations on returning to the mixed diet. Twenty-four-hour ratios of urinary gamma-carboxyglutamic acid to creatinine were unchanged with the supplemented diet; however, excretion declined to 91 +/- 2% of baseline after 10 d on the mixed diet (P = 0.01). These results show that undercarboxylated osteocalcin, plasma Phylloquinone, and urinary gamma-carboxyglutamic acid excretion appear to be sensitive measures of vitamin K nutritional status because all of these variables were responsive to changes in dietary intake.

  • assessment of dietary Phylloquinone intake and vitamin k status in postmenopausal women
    European Journal of Clinical Nutrition, 1995
    Co-Authors: Sarah L. Booth, Lori J. Sokoll, Maureen E Obrien, Katherine L Tucker, Bess Dawsonhughes, James A. Sadowski
    Abstract:

    Objective To examine the relationship between dietary Phylloquinone intake and vitamin K status of postmenopausal Caucasian women. Design Cross-sectional study, in which dietary intake was estimated using weighed record techniques and vitamin K status was measured by a single plasma Phylloquinone concentration and 24-h urinary gamma-carboxyglutamic acid (Gla) excretion. Setting The metabolic research unit at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA. Subjects 402 healthy postmenopausal Caucasian women who were participating in a randomized trial to determine the effect of calcium supplementation on bone loss. Of the original group, 362 had complete weighed diet records, 358 had corresponding plasma Phylloquinone concentrations, and 346 had corresponding urinary Gla measurements. Results There was a significant correlation (r = 0.13, P = 0.01) between total dietary intake of Phylloquinone (geometric mean = 89 micrograms/day) and plasma Phylloquinone levels (mean = 1.12 nmol/l). Dietary intake was neither correlated with urinary Gla excretion (mean = 4.0 mumol/mmol creatinine) nor did it vary by season. The ratio of intra- to interindividual variance in Phylloquinone intake was 2.6, from which it was estimated that 5 days of independent recording is necessary to estimate true usual dietary intake, assuming a correlation of 0.8. Conclusions A weighed record has the potential to be a reliable method for estimating dietary intakes of vitamin K which relate to plasma Phylloquinone levels used as an indicator of vitamin K status in postmenopausal Caucasian women.

  • Phylloquinone vitamin k1 content of foods in the u s food and drug administration s total diet study
    Journal of Agricultural and Food Chemistry, 1995
    Co-Authors: Sarah L. Booth, James A. Sadowski
    Abstract:

    Two hundred sixty-one foods from the U.S. Food and Drug Administration's Total Diet Study were analyzed for Phylloquinone (vitamin K 1 ) using a high-performance liquid chromatographic method that incorporates postcolumn reduction of the quinone, followed by fluorescence detection of the hydroquinone form of the vitamin. Green, leafy vegetables still appear to be the predominant dietary source of this vitamin (113-440 μg of Phylloquinone/100 g of vegetable), followed by certain vegetable oils that are derived from vegetables or seeds containing large concentrations of Phylloquinone. Some mixed dishes contain moderate amounts of Phylloquinone that are attributable to the vegetable oils used in their preparation. Other foods, such as certain meats, brewed beverages, soft drinks, and alcoholic beverages, contained negligible amounts of Phylloquinone. These data expand and improve the quality and quantity of the Phylloquinone food composition table and will be used to prioritize future analyses.